证券代码：300030 证券简称：阳普医疗 公告编号：2023-054 阳普医疗科技股份有限公司 关于子公司与湖南郴州经济开发区管理委员会 签署解除招商项目合作合同暨协商收回协议书的公告 2017 年 8 月 31 日，阳普医疗科技股份有限公司（以下简称"公司"）全资 子公司阳普医疗(郴州)有限公司（以下简称"郴州阳普"）与湖南郴州经济开发 区管理委员会（以下简称"郴州开发区管委会"）签署了招商项目合作合同书， 用于建设医疗健康产业园。具体内容详见公司在中国证券监督管理委员会指定的 创业板信息披露网站巨潮资讯网（www.cninfo.com.cn）的公告《关于子公司与湖 南郴州经济开发区管理委员会签署招商项目合作合同书的公告》（公告编号： 2017-113）。 2017 年 9 月，郴州阳普竞得 TG2017027 地块，土地面积 66476.4 ㎡，并于 2018 年 1 月获得不动产权证书，证书号为湘（2018）北湖不动产权第 0000155 号。2020 年 6 月-2022 年 4 月期间，郴州阳普建成标准厂房、发动机房、配电房等建筑面 积共计 10407.61 ㎡，并获得不动产权证，证书号为湘（20 ...

Group 1: Company Overview - Yangpu Medical Technology Co., Ltd. is focused on molecular diagnostics and has made significant investments in this area since 2021 [1] - The company has a competitive advantage in molecular diagnostic products, featuring advanced technology and high automation, which reduces human error [1] Group 2: Sales Channels - Domestic direct sales account for approximately 25% of the sales of vacuum blood collection tubes, while distribution channels make up about 75% [2] - The primary sales focus for vacuum blood collection tubes is hospitals, supplemented by third-party testing institutions [2] Group 3: Product Certification and Market Reach - The company holds multiple certifications including EU CE, US FDA, and market access qualifications in Canada, Brazil, and over 100 other countries [2] - The quality management system meets various international standards such as ISO9001, ISO13485, and others, serving nearly 10,000 well-known medical institutions globally [2] Group 4: Research and Development - In 2022, the company's R&D investment accounted for 6.14% of revenue, an increase of 0.61 percentage points from the previous year [2] - The company received 24 new patent authorizations in 2022, including 3 domestic invention patents and 20 utility model patents [2] - Ongoing projects include the development of an AI-based automatic thromboelastography system and a molecular diagnostic blood collection tube project [2]

Financial Performance - The company's operating revenue for Q1 2023 was ¥158,563,957.54, a decrease of 11.69% compared to the same period last year[4] - Net profit attributable to shareholders was ¥13,633,861.49, representing a significant increase of 136.16% year-on-year[4] - The net profit after deducting non-recurring gains and losses was ¥12,559,469.71, up 132.23% from the previous year[4] - The basic earnings per share improved to ¥0.04, compared to a loss of ¥0.12 in the same quarter last year, marking a 133.33% increase[4] - The company reported a significant increase in operating profit to ¥15,762,432.61, up 144.53% year-on-year[12] - Total operating revenue for Q1 2023 was ¥158,563,957.54, a decrease of 11.7% compared to ¥179,558,042.65 in Q1 2022[30] - Net profit for Q1 2023 reached ¥1,728,803.13, compared to a net loss of ¥37,314,648.73 in Q1 2022, marking a significant turnaround[30] - The company reported an operating profit of ¥15,762,432.61 in Q1 2023, compared to an operating loss of ¥35,397,536.95 in the same period last year[30] Assets and Liabilities - Total assets at the end of Q1 2023 were ¥1,575,685,333.65, reflecting a 1.12% increase from the end of the previous year[4] - The company’s total liabilities increased to ¥740,902,549.11 from ¥737,568,558.82 year-over-year[30] - The total equity attributable to shareholders of the parent company rose to ¥797,984,297.23, up from ¥784,349,030.45 in the previous year[30] Cash Flow - The cash flow from operating activities showed a slight improvement, with a net outflow of ¥17,982,500.06, a 7.92% reduction in outflow compared to the previous year[4] - The net cash flow from investment activities was ¥15,812,418.98, a turnaround of 144.63% compared to the previous period[14] - The net cash flow from operating activities for Q1 2023 was -¥17,982,500.06, compared to -¥19,528,640.89 in Q1 2022, indicating a slight improvement[35] - The company reported a total cash outflow from operating activities of ¥203,456,313.74 in Q1 2023, down from ¥232,021,366.27 in Q1 2022, indicating improved cash management[35] - The company’s cash flow management strategies appear to be improving, as evidenced by the reduced net cash outflow from operating activities year-over-year[35] Investment and Financing - Investment income for the quarter was ¥10,528,707.60, a turnaround from a loss of ¥39,719,251.68 in the same period last year, representing a 126.51% increase[12] - The company received tax refunds of ¥2,263,481.06, an increase of 31.64% compared to the previous period[14] - Investment income received amounted to ¥19,973,330.11, a significant increase of 9052.46% due to dividends from Shenzhen Yanghe[14] - Short-term bank loans increased by 43.58%, with cash received from borrowings totaling ¥153,500,000.00[14] - The company paid out ¥4,623,453.81 in dividends and interest, an increase of 36.79% due to higher bank loan interest payments[14] - Cash inflow from financing activities increased to ¥153,507,700.00 in Q1 2023, up from ¥106,910,000.00 in Q1 2022, leading to a net cash flow from financing activities of ¥28,881,444.39, compared to ¥8,578,653.52 in the previous year[35] Market and Product Development - The company is actively expanding its market presence internationally, engaging with distributors and end-users in the Middle East, Europe, Africa, and West Asia[23] - The company launched the "Return to Simplicity - Needle-Free Venous Blood Collection Design Competition" to promote innovative and safer medical products[21] - The company participated in the 2023 Arab International Medical Laboratory Instruments and Equipment Exhibition, showcasing its vacuum blood collection system and smart laboratory solutions[23] - The company is committed to enhancing its core technology research and development capabilities, aiming for continuous innovation and improved product value[19] - The company's main products, "disposable vacuum blood collection tubes" and "thromboelastography instruments," were recognized as "2022 Guangdong Province Excellent High-tech Products" by the Guangdong Provincial High-tech Enterprise Association[19] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 30,840[15] - The top shareholder, Deng Guanhua, holds 15.91% of shares, totaling 49,194,555 shares, with 38,466,416 shares pledged[15] - The company has a total of 40,777,333 restricted shares at the beginning of the period, with 2,240,631 shares released during the period[18]

Financial Performance - The company reported a significant decline in net profit, primarily due to reduced investment income and asset impairment [3]. - The company's operating revenue for 2022 was ¥710,768,471.36, a decrease of 11.14% compared to ¥799,833,986.91 in 2021 [22]. - The net profit attributable to shareholders was -¥198,300,074.80 in 2022, representing a significant decline of 1,167.94% from ¥18,568,529.32 in 2021 [22]. - The cash flow from operating activities was ¥42,478,058.14, down 75.27% from ¥171,738,972.42 in the previous year [22]. - The total assets at the end of 2022 amounted to ¥1,558,180,092.05, a decrease of 14.62% from ¥1,825,050,178.44 at the end of 2021 [22]. - The company reported a basic earnings per share of -¥0.64 for 2022, a decline of 1,166.67% from ¥0.06 in 2021 [22]. - The weighted average return on equity was -22.19% in 2022, down 24.04 percentage points from 1.85% in 2021 [22]. - The company achieved a gross margin of 36.45% in the medical industry, down 3.27% from the previous year [95]. - The company reported a total revenue of 1.5 billion RMB for the fiscal year 2022, representing a year-over-year growth of 15% [180]. Business Strategy and Operations - The core business and competitive strengths of the company have not undergone significant changes, and there are no major risks to its ongoing operations [3]. - The company plans not to distribute cash dividends, issue bonus shares, or increase capital using reserves [4]. - Future operational risks and corresponding countermeasures are detailed in the management discussion section of the report [3]. - The company emphasizes the importance of understanding the differences between plans, forecasts, and commitments regarding future performance [3]. - The company is focusing on expanding its presence in county-level and grassroots hospitals, leveraging partnerships with leading third-party medical testing laboratories [66]. - The company is committed to continuous improvement in product quality and customer satisfaction, positioning itself as a leader in the medical technology industry [64]. - The company is actively pursuing market expansion strategies, particularly in the healthcare technology sector, to increase its market share [75]. - The company is exploring potential mergers and acquisitions to enhance its technological capabilities and market presence [76]. - The company aims to enhance its core competitive advantages by focusing on strategic products, particularly in the IVD sector, and expanding into third-party testing services [144]. Research and Development - The company has a dedicated R&D team of over 300 professionals, focusing on innovation across IVD, smart healthcare, and testing services [59]. - The company has developed a robust pipeline of new products, including various laboratory management systems and medical software, which are expected to launch in the upcoming quarters [76]. - The company is investing 100 million RMB in R&D for new technologies aimed at enhancing diagnostic capabilities [180]. - The company has completed several R&D projects aimed at product miniaturization and image optimization, enhancing product competitiveness [104]. - The company is focusing on expanding its product range through customized R&D projects, which are currently ongoing [104]. - The company has successfully registered various medical devices, including a hemostatic band and a disposable sampling device, with long-term validity [111]. Market Trends and Industry Insights - The medical device industry in China experienced a revenue growth rate of approximately 12% in 2022, significantly higher than the overall growth rate of the pharmaceutical industry [31]. - In 2022, China's medical device industry export scale reached $19.093 billion, with the market size expected to reach ¥958.2 billion, reflecting a compound annual growth rate (CAGR) of approximately 17.5% over the past seven years, making it the second-largest market globally after the U.S. [33]. - The global IVD market grew from $83.3 billion in 2020 to $117 billion in 2021, with projections indicating it will reach $32.75 billion by 2025, corresponding to a CAGR of 15.3% from 2020 to 2025 [34]. - The company aims to transition towards IVD (in vitro diagnostics) and expand its product offerings to include rapid diagnostics for cardiovascular diseases and molecular diagnostics for tumor companion diagnostics [142]. Corporate Governance - The board of directors consists of 9 members, including 1 chairman and 3 independent directors, ensuring effective decision-making and governance [159]. - The supervisory board, comprising 3 members, is responsible for safeguarding shareholder rights and overseeing the company's legal operations [160]. - The company emphasizes accurate and timely information disclosure, with the chairman as the primary responsible person for disclosures [162]. - The company has implemented a performance evaluation and incentive mechanism for directors and senior management to align with its development goals [164]. - The company has a structured decision-making process for determining the remuneration of its directors and senior management, based on operational performance and industry benchmarks [184]. Financial Management - The company has a stable supply chain, with most raw materials sourced domestically, ensuring quality and safety through a rigorous supplier evaluation process [62]. - The company reported a total sales expense of ¥126.05 million in 2022, an increase of 11.60% from ¥112.95 million in 2021 [103]. - The company’s top five customers contributed a total sales amount of ¥98.43 million, representing 13.85% of the annual sales total [101]. - The total procurement amount from the top five suppliers was ¥79.25 million, accounting for 24.29% of the annual procurement total [102]. - The company has a clear profit distribution policy, ensuring the interests of all shareholders are protected [197]. Challenges and Risks - The company faces risks from industry policy changes, particularly in the highly regulated medical sector, which could impact operations if strategies are not adjusted accordingly [149]. - The company acknowledges risks in new product and technology development, including potential delays and failures due to various factors [150]. - The company is exposed to overseas market sales risks due to geopolitical uncertainties affecting major clients in various countries [152]. Future Outlook - The company has outlined a future outlook that includes a projected revenue growth rate of over 20% for the next fiscal year, driven by new product launches and market expansion [75]. - The company plans to continue its market expansion and product development strategies in the medical device sector [112]. - The company is committed to improving its research and development capabilities to drive future growth in the medical technology sector [113].

证券代码：300030 证券简称：阳普医疗 公告编号：2023-025 阳普医疗科技股份有限公司 关于召开 2022 年度业绩说明会的公告 本公司及其董事会全体成员保证公告内容真实、准确和完整，没有虚假记 载、误导性陈述或重大遗漏。 阳普医疗科技股份有限公司（以下简称"公司"）已于 2023 年 4 月 27 日在 巨潮资讯网上披露了《2022 年年度报告》及《2022 年年度报告摘要》。为便于 广大投资者更加全面深入地了解公司情况，公司定于 2023 年 05 月 05 日（星期 五）15:30-17:30 在"价值在线"（www.ir-online.cn）举办公司 2022 年度业 绩说明会，与投资者进行沟通和交流，广泛听取投资者的意见和建议。 一、说明会召开的时间、地点和方式 会议召开时间：2023 年 05 月 05 日（星期五）15:30-17:30 会议召开地点：价值在线（www.ir-online.cn） 会议召开方式：网络互动方式 二、参加人员 公司董事长兼总经理邓冠华先生、独立董事谢晓尧先生、财务负责人闫红玉 女士、董事会秘书余威先生（如遇特殊情况，出席人员可能进行调整）。 三、投资者参与方 ...

Group 1: Product Performance - The overall growth of blood collection tube products is ongoing, but due to increased exports, the gross margin has declined, and the product's proportion is expected to decrease in the future [1] - Both self-produced and agency IVD products are increasing, and their future revenue will play a significant role [1] Group 2: Partnerships and Collaborations - The registration of products related to the partnership with Germany's ViraSense has been delayed, but the company is actively promoting progress and hopes to continue collaboration with the German side [1] - The company and its subsidiary, Ruida Medical, have obtained exclusive agency rights for Philips' basic medical products in South China, which will be distributed by distributors [1] Group 3: Future Directions - The company's future investment and acquisition direction will focus on five major product strategies: diagnosis, nursing anesthesia, imaging, pharmaceuticals, and health services [1] - The profit distribution plan and dividend strategy for the fiscal year 2014 have been announced and will be executed in accordance with relevant laws and regulations [1]

证券代码：阳普医疗 证券简称：300030 编号： 广州阳普医疗科技股份有限公司投资者关系活动记录表 | --- | --- | --- | |----------------------------|-----------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ...

证券代码：阳普医疗 证券简称：300030 编号： 广州阳普医疗科技股份有限公司投资者关系活动记录表 | --- | --- | --- | |----------------------------|-----------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ...

Group 1: Company Overview - The company has five product strategic platforms and one medical service platform, including medical laboratory diagnostics, imaging diagnostics, nursing and anesthesia products, biopharmaceutical materials, and respiratory health management [2] - The main customer base is hospitals, particularly top-tier hospitals, with plans to gradually introduce civilian products like masks and air purifiers to households [2] Group 2: Financial Performance - The company has high product gross margins but low net profits due to the limited profit contribution from newly established subsidiaries [2] - Continuous development requires financial support, indicating a need for diversified financing in the future [2] Group 3: Competitive Advantages - The management team comprises experienced professionals from renowned companies like Johnson & Johnson and Procter & Gamble, contributing to a strong leadership brand in the medical device industry [3] - The company focuses on high-end markets, resulting in stable growth in sales of blood collection tubes and needles, primarily from top-tier hospitals [3] Group 4: Industry Challenges and Opportunities - Medical reforms present both opportunities and challenges, increasing competition while highlighting the government's focus on the healthcare sector [3] - The company invests significantly in R&D for blood collection tubes, utilizing advanced technology and high-end imported materials to ensure the accuracy of blood sample testing [3]

Financial Performance - In 2020, the company achieved total revenue of 919 million, a year-on-year increase of 59.85%, primarily driven by sales of the microbiological transport system (312 million) and masks (118 million) [1] - The net profit attributable to the parent company in 2020 was 163 million, a significant increase of 524.48%, with the listing of subsidiary Weisi Medical contributing 79.948 million to this profit [2] - In Q1 2021, the company reported revenue of 231 million, up 56.43% year-on-year, with a net profit of 33 million, reflecting a growth of 201.56% [1] Marketing Strategy - The company plans to strengthen its national sales network and increase sales personnel to capture larger market shares across multiple provinces [2] - Marketing will be a key focus for the next two years, aiming to enhance collaboration and expand market presence [2] Product Development - The company is committed to full hospital informationization and aims to develop liquid biopsy, genetic diagnosis, and in vitro diagnostics [2] - New product selection is based on principles of large market potential, high added value, low competition, and light asset requirements [2] - The integrated molecular diagnostic workstation and rare single-cell separation platform are key innovations, with the former expected to receive certification this year [2][4] Market Position and Competition - The company holds the largest market share for vacuum blood collection tubes in Guangdong, while actively monitoring collective procurement policies in other provinces [3] - The thromboelastography product is positioned as a proprietary brand with significant market potential, estimated to exceed 10 billion [3][4] Future Outlook - The company aims to enhance product gross margins and execute improvements while maintaining steady growth in core businesses [4] - A balanced approach between long-term development and short-term profits will guide the company’s strategy in 2021, focusing on cardiovascular disease and molecular diagnostic technologies [4]